Rituximab for immunologic renal disease: What the nephrologist needs to know

Autoimmunity Reviews

Volumn 16, Issue 6, 2017, Pages 633-643

  Kronbichler, Andreas ^a   Windpessl, Martin ^b   Pieringer, Herwig ^c,d   Jayne, David R W ^e,f  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b Klinikum Wels Grieskirchen GmbH   (Austria)

^c KEPLER UNIVERSITY HOSPITAL   (Austria)

^d PARACELSUS MEDICAL UNIVERSITY   (Austria)

^e ADDENBROOKE S HOSPITAL   (United Kingdom)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

B cell depletion; CD20; Infections; Nephrology; Renal diseases; Rituximab; Side effects

Indexed keywords

ANTIBIOTIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIVIRUS AGENT; AZATHIOPRINE; CHLORAMBUCIL; CORTICOSTEROID; COTRIMOXAZOLE; DIPHENHYDRAMINE; ENTECAVIR; GLUCOCORTICOID; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; LAMIVUDINE; PARACETAMOL; PLACEBO; PNEUMOCOCCUS VACCINE; RITUXIMAB; TENOFOVIR; TETANUS ANTIBODY; TETANUS TOXOID; VACCINE; IMMUNOLOGIC FACTOR;

ANTIVIRAL THERAPY; BRONCHOSPASM; CLINICAL TRIAL (TOPIC); CORTICOSTEROID THERAPY; DRUG EFFICACY; DRUG INFORMATION; DRUG MECHANISM; DRUG SAFETY; ELIMINATION HALF-LIFE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HYPOTENSION; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNOCOMPROMISED PATIENT; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFUSION RELATED REACTION; INTERSTITIAL LUNG DISEASE; KIDNEY DISEASE; LUPUS ERYTHEMATOSUS NEPHRITIS; NEPHROLOGIST; NEUTROPENIA; PATIENT COUNSELING; PHARMACOKINETIC PARAMETERS; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; PREGNANCY; PREMATURE LABOR; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEINURIA; REVIEW; RISK ASSESSMENT; SPONTANEOUS ABORTION; VACCINATION; VIRUS REACTIVATION; VOLUME OF DISTRIBUTION; IMMUNE SYSTEM DISEASES; KIDNEY DISEASES;

HUMANS; IMMUNE SYSTEM DISEASES; IMMUNOLOGIC FACTORS; KIDNEY DISEASES; RITUXIMAB;

EID: 85018793966     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2017.04.007     Document Type: Review

References (180)

1. Stone, J.H., Merkel, P.A., Spiera, R., Seo, P., Langford, C.A., Hoffman, G.S., et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363 (2010), 221–232.
2. Jones, R.B., Tervaert, J.W., Hauser, T., Luqmani, R., Morgan, M.D., Peh, C.A., et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363 (2010), 211–220.
3. Rovin, B.H., Furie, R., Latinis, K., Looney, R.J., Fervenza, F.C., Sanchez-Guerrero, J., et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 64 (2012), 1215–1226.
4. Chakravarty, E.F., Murray, E.R., Kelman, A., Farmer, P., Pregnancy outcomes after maternal exposure to rituximab. Blood 117 (2011), 1499–1506.
5. Pieringer, H., Parzer, I., Wohrer, A., Reis, P., Oppl, B., Zwerina, J., IgG4- related disease: an orphan disease with many faces. Orphanet J Rare Dis, 9, 2014, 110.
6. Iorio, R., Damato, V., Alboini, P.E., Evoli, A., Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis. J Neurol 262 (2015), 1115–1119.
7. Remuzzi, G., Chiurchiu, C., Abbate, M., Brusegan, V., Bontempelli, M., Ruggenenti, P., Rituximab for idiopathic membranous nephropathy. Lancet 360 (2002), 923–924.
8. Feehally, J., Targeted therapies: is there a role for rituximab in nephrotic syndrome?. Nat Rev Nephrol 10 (2014), 245–247.
9. Evans, R., Salama, A.D., Update on rituximab: an established treatment for all immune-mediated kidney diseases?. Nephron Clin Pract 126 (2014), 97–109.
10. Roccatello, D., Sciascia, S., Di Simone, D., Solfietti, L., Naretto, C., Fenoglio, R., et al. New insights into immune mechanisms underlying response to rituximab in patients with membranous nephropathy: a prospective study and a review of the literature. Autoimmun Rev 15 (2016), 529–538.
11. Hoffman, W., Lakkis, F.G., Chalasani, G., B cells, antibodies, and more. Clin J Am Soc Nephrol 11 (2016), 137–154.
12. Yeo, S.C., Liew, A., Biologic agents in the treatment of glomerulonephritides. Nephrol Ther 20 (2015), 767–787.
13. Santoro, D., Pellicano, V., Visconti, L., Trifiro, G., Cernaro, V., Buemi, M., Monoclonal antibodies for renal diseases: current concepts and ongoing treatments. Expert Opin Biol Ther 15 (2015), 1119–1143.
14. Salama, A.D., Pusey, C.D., Drug insight: rituximab in renal disease and transplantation. Nat Clin Pract Nephrol 2 (2006), 221–230.
15. Visentini, M., Tinelli, C., Colantuono, S., Monti, M., Ludovisi, S., Gragnani, L., et al. Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: phase II clinical trial and systematic review. Autoimmun Rev 14 (2015), 889–896.
16. Reynaud, Q., Durieu, I., Dutertre, M., Ledochowski, S., Durupt, S., Michallet, A.S., et al. Efficacy and safety of rituximab in auto-immune hemolytic anemia: a meta-analysis of 21 studies. Autoimmun Rev 14 (2015), 304–313.
17. O'Connor, K., Liddle, C., Prospective data collection of off-label use of rituximab in Australian public hospitals. Intern Med J 43 (2013), 863–870.
18. Danes, I., Agusti, A., Vallano, A., Martinez, J., Alerany, C., Ferrer, A., et al. Available evidence and outcome of off-label use of rituximab in clinical practice. Eur J Clin Pharmacol 69 (2013), 1689–1699.
19. Cragg, M.S., Walshe, C.A., Ivanov, A.O., Glennie, M.J., The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 8 (2005), 140–174.
20. Tedder, T.F., Engel, P., CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 15 (1994), 450–454.
21. Pescovitz, M.D., Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transplant 6 (2006), 859–866.
22. Kimby, E., Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 31 (2005), 456–473.
23. Winter, O., Dame, C., Jundt, F., Hiepe, F., Pathogenic long-lived plasma cells and their survival niches in autoimmunity, malignancy, and allergy. J Immunol 189 (2012), 5105–5111.
24. Smith, K.G., Jones, R.B., Burns, S.M., Jayne, D.R., Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum 54 (2006), 2970–2982.
25. Fornoni, A., Sageshima, J., Wei, C., Merscher-Gomez, S., Aguillon-Prada, R., Jauregui, A.N., et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med, 3, 2011, 85ra46.
26. Faul, C., Donnelly, M., Merscher-Gomez, S., Chang, Y.H., Franz, S., Delfgaauw, J., et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 14 (2008), 931–938.
27. SMPC, MabThera, INN-rituximab - EMA - Europa, in: Editor (Ed.) (Eds.), Book MabThera, INN-rituximab - EMA - Europa, pp.
28. Salar, A., Avivi, I., Bittner, B., Bouabdallah, R., Brewster, M., Catalani, O., et al. Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase IB study. J Clin Oncol 32 (2014), 1782–1791.
29. Ahmed, A.R., Shetty, S., A comprehensive analysis of treatment outcomes in patients with pemphigus vulgaris treated with rituximab. Autoimmun Rev 14 (2015), 323–331.
30. Jones, R.B., Ferraro, A.J., Chaudhry, A.N., Brogan, P., Salama, A.D., Smith, K.G., et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 60 (2009), 2156–2168.
31. Cravedi, P., Ruggenenti, P., Sghirlanzoni, M.C., Remuzzi, G., Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2 (2007), 932–937.
32. Seitz-Polski, B., Debiec, H., Dahan, K., Benzaken, S., Ronco, P.M., Rituximab residual levels and neutralizing anti-rituximab antibodies (ab) are associated with response to treatment in patients with PLA2R-related membranous nephropathy (MN). 2016, Kidney Week, Am Soc Nephrol, Chicago, IL [pp.].
33. Looney, R.J., Anolik, J.H., Campbell, D., Felgar, R.E., Young, F., Arend, L.J., et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 50 (2004), 2580–2589.
34. Golay, J., Semenzato, G., Rambaldi, A., Foa, R., Gaidano, G., Gamba, E., et al. Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. MAbs 5 (2013), 826–837.
35. Fervenza, F.C., Abraham, R.S., Erickson, S.B., Irazabal, M.V., Eirin, A., Specks, U., et al. Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin J Am Soc Nephrol 5 (2010), 2188–2198.
36. Mills, J.R., Cornec, D., Dasari, S., Ladwig, P.M., Hummel, A.M., Cheu, M., et al. Using mass spectrometry to quantify rituximab and perform individualized immunoglobulin phenotyping in ANCA-associated vasculitis. Anal Chem 88 (2016), 6317–6325.
37. Cartron, G., Blasco, H., Paintaud, G., Watier, H., Le Guellec, C., Pharmacokinetics of rituximab and its clinical use: thought for the best use?. Crit Rev Oncol Hematol 62 (2007), 43–52.
38. Puisset, F., White-Koning, M., Kamar, N., Huart, A., Haberer, F., Blasco, H., et al. Population pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody-mediated disease. Br J Clin Pharmacol 76 (2013), 734–740.
39. Counsilman, C.E., Jol-van der Zijde, C.M., Stevens, J., Cransberg, K., Bredius, R.G., Sukhai, R.N., Pharmacokinetics of rituximab in a pediatric patient with therapy-resistant nephrotic syndrome. Pediatr Nephrol 30 (2015), 1367–1370.
40. Jillella, A.P., Dainer, P.M., Kallab, A.M., Ustun, C., Treatment of a patient with end-stage renal disease with rituximab: pharmacokinetic evaluation suggests rituximab is not eliminated by hemodialysis. Am J Hematol 71 (2002), 219–222.
41. Vieira, C.A., Agarwal, A., Book, B.K., Sidner, R.A., Bearden, C.M., Gebel, H.M., et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation 77 (2004), 542–548.
42. McDonald, V., Manns, K., Mackie, I.J., Machin, S.J., Scully, M.A., Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura. J Thromb Haemost 8 (2010), 1201–1208.
43. Walsh, M., Merkel, P.A., Peh, C.A., Szpirt, W., Guillevin, L., Pusey, C.D., et al. Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial. Trials, 14, 2013, 73.
44. Albert, D., Dunham, J., Khan, S., Stansberry, J., Kolasinski, S., Tsai, D., et al. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus. Ann Rheum Dis 67 (2008), 1724–1731.
45. Zarkhin, V., Li, L., Kambham, N., Sigdel, T., Salvatierra, O., Sarwal, M.M., A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation. Am J Transplant 8 (2008), 2607–2617.
46. Dahan, K., Debiec, H., Plaisier, E., Cachanado, M., Rousseau, A., Wakselman, L., et al. Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up. J Am Soc Nephrol 28 (2017), 348–358.
47. Besada, E., Koldingsnes, W., Nossent, J.C., Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: results from a single centre. Rheumatology 52 (2013), 2041–2047.
48. Roberts, D.M., Jones, R.B., Smith, R.M., Alberici, F., Kumaratne, D.S., Burns, S., et al. Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease. J Autoimmun 57 (2015), 60–65.
49. Knight, A., Sundstrom, Y., Borjesson, O., Bruchfeld, A., Malmstrom, V., Gunnarsson, I., Late-onset neutropenia after rituximab in ANCA-associated vasculitis. Scand J Rheumatol 45 (2016), 404–407.
50. Giezen, T.J., Mantel-Teeuwisse, A.K., ten Berg, M.J., Straus, S.M., Leufkens, H.G., van Solinge, W.W., et al. Rituximab-induced thrombocytopenia: a cohort study. Eur J Haematol 89 (2012), 256–266.
51. Gea-Banacloche, J.C., Rituximab-associated infections. Semin Hematol 47 (2010), 187–198.
52. Byrd, J.C., Waselenko, J.K., Maneatis, T.J., Murphy, T., Ward, F.T., Monahan, B.P., et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol 17 (1999), 791–795.
53. Chung, C.H., Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist 13 (2008), 725–732.
54. Peters, H.P., van de Kar, N.C., Wetzels, J.F., Rituximab in minimal change nephropathy and focal segmental glomerulosclerosis: report of four cases and review of the literature. Neth J Med 66 (2008), 408–415.
55. Pritchard, C.H., Greenwald, M.W., Kremer, J.M., Gaylis, N.B., Rigby, W., Zlotnick, S., et al. Safety of infusing rituximab at a more rapid rate in patients with rheumatoid arthritis: results from the RATE-RA study. BMC Musculoskelet Disord, 15, 2014, 177.
56. Breslin, S., Cytokine-release syndrome: overview and nursing implications. Clin J Oncol Nurs 11 (2007), 37–42.
57. Lenz, H.J., Management and preparedness for infusion and hypersensitivity reactions. Oncologist 12 (2007), 601–609.
58. van Vollenhoven, R.F., Emery, P., Bingham, C.O. III, Keystone, E.C., Fleischmann, R., Furst, D.E., et al. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol 37 (2010), 558–567.
59. Ruggenenti, P., Cravedi, P., Chianca, A., Perna, A., Ruggiero, B., Gaspari, F., et al. Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol 23 (2012), 1416–1425.
60. Pendergraft, W.F. III, Cortazar, F.B., Wenger, J., Murphy, A.P., Rhee, E.P., Laliberte, K.A., et al. Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis. Clin J Am Soc Nephrol 9 (2014), 736–744.
61. Vogel, W.H., Infusion reactions: diagnosis, assessment, and management. Clin J Oncol Nurs 14 (2010), E10–E21.
62. Larsen, J.L., Jacobsen, S., Rapid infusion with rituximab: short term safety in systemic autoimmune diseases. Rheumatol Int 33 (2013), 529–533.
63. Marco, H., Smith, R.M., Jones, R.B., Guerry, M.J., Catapano, F., Burns, S., et al. The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease. BMC Musculoskelet Disord, 15, 2014, 178.
64. Besada, E., Koldingsnes, W., Nossent, J.C., Serum immunoglobulin levels and risk factors for hypogammaglobulinaemia during long-term maintenance therapy with rituximab in patients with granulomatosis with polyangiitis. Rheumatology 53 (2014), 1818–1824.
65. Venhoff, N., Effelsberg, N.M., Salzer, U., Warnatz, K., Peter, H.H., Lebrecht, D., et al. Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides. PLoS One, 7, 2012, e37626.
66. Alberici, F., Smith, R.M., Jones, R.B., Roberts, D.M., Willcocks, L.C., Chaudhry, A., et al. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. Rheumatology 54 (2015), 1153–1160.
67. Makatsori, M., Kiani-Alikhan, S., Manson, A.L., Verma, N., Leandro, M., Gurugama, N.P., et al. Hypogammaglobulinaemia after rituximab treatment-incidence and outcomes. QJM 107 (2014), 821–828.
68. Delbe-Bertin, L., Aoun, B., Tudorache, E., Lapillone, H., Ulinski, T., Does rituximab induce hypogammaglobulinemia in patients with pediatric idiopathic nephrotic syndrome?. Pediatr Nephrol 28 (2013), 447–451.
69. Fujinaga, S., Ozawa, K., Sakuraya, K., Yamada, A., Shimizu, T., Late-onset adverse events after a single dose of rituximab in children with complicated steroid-dependent nephrotic syndrome. Clin Nephrol 85 (2016), 340–345.
70. Aguiar, R., Araujo, C., Martins-Coelho, G., Isenberg, D., Use of rituximab in systemic lupus erythematosus: a single center experience over 14 years. Arthritis Care Res 69 (2017), 257–262.
71. Rituximab Vasculitis Maintenance Study (RITAZAREM), NCT01697267. 2017.
72. Barmettler, S., Price, C., Continuing IgG replacement therapy for hypogammaglobulinemia after rituximab—for how long?. J Allergy Clin Immunol 136 (2015), 1407–1409.
73. Monaco, W.E., Jones, J.D., Rigby, W.F., Rituximab associated late-onset neutropenia-a rheumatology case series and review of the literature. Clin Rheumatol 35 (2016), 2457–2462.
74. Wolach, O., Bairey, O., Lahav, M., Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature. Medicine 89 (2010), 308–318.
75. Wolach, O., Shpilberg, O., Lahav, M., Neutropenia after rituximab treatment: new insights on a late complication. Curr Opin Hematol 19 (2012), 32–38.
76. Dunleavy, K., Tay, K., Wilson, W.H., Rituximab-associated neutropenia. Semin Hematol 47 (2010), 180–186.
77. Tesfa, D., Gelius, T., Sander, B., Kimby, E., Fadeel, B., Palmblad, J., et al. Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesis. Med Oncol 25 (2008), 374–379.
78. Kamei, K., Takahashi, M., Fuyama, M., Saida, K., Machida, H., Sato, M., et al. Rituximab-associated agranulocytosis in children with refractory idiopathic nephrotic syndrome: case series and review of literature. Nephrol Dial Transplant 30 (2015), 91–96.
79. Salmon, J.H., Cacoub, P., Combe, B., Sibilia, J., Pallot-Prades, B., Fain, O., et al. Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry. RMD Open, 1, 2015, e000034.
80. FDA, Boxed warning and new recommendations to decrease the risk of hepatitis B reactivation with the immune-suppressing and anti-cancer drugs Arzerra (ofatumumab) and Rituxan (rituximab). 2013 [pp.].
81. Chen, X.Q., Peng, J.W., Lin, G.N., Li, M., Xia, Z.J., The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAg-positive patients with diffuse large B-cell lymphoma undergoing prolonged rituximab therapy. Med Oncol 29 (2012), 1237–1241.
82. Lee, J., Lee, J.G., Kim, S., Song, S.H., Kim, B.S., Kim, H.O., et al. The effect of rituximab dose on infectious complications in ABO-incompatible kidney transplantation. Nephrol Dial Transplant 31 (2016), 1013–1021.
83. Di Bisceglie, A.M., Lok, A.S., Martin, P., Terrault, N., Perrillo, R.P., Hoofnagle, J.H., Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg?. Hepatology 61 (2015), 703–711.
84. Dyson, J.K., Jopson, L., Ng, S., Lowery, M., Harwood, J., Waugh, S., et al. Improving testing for hepatitis B before treatment with rituximab. Eur J Gastroenterol Hepatol 28 (2016), 1172–1178.
85. Reddy, K.R., Beavers, K.L., Hammond, S.P., Lim, J.K., Falck-Ytter, Y.T., American Gastroenterological Association, American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 148 (2015), 215–219.
86. Sandherr, M., Hentrich, M., von Lilienfeld-Toal, M., Massenkeil, G., Neumann, S., Penack, O., et al. Antiviral prophylaxis in patients with solid tumours and haematological malignancies—update of the guidelines of the infectious diseases working party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). Ann Hematol 94 (2015), 1441–1450.
87. Hwang, J.P., Somerfield, M.R., Alston-Johnson, D.E., Cryer, D.R., Feld, J.J., Kramer, B.S., et al. Hepatitis B virus screening for patients with cancer before therapy: American Society of Clinical Oncology provisional clinical opinion update. J Clin Oncol 33 (2015), 2212–2220.
88. Huang, Y.H., Hsiao, L.T., Hong, Y.C., Chiou, T.J., Yu, Y.B., Gau, J.P., et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol 13 (2013), 2765–2772.
89. Gossmann, J., Scheuermann, E.H., Kachel, H.G., Geiger, H., Hauser, I.A., Reactivation of hepatitis B two years after rituximab therapy in a renal transplant patient with recurrent focal segmental glomerulosclerosis: a note of caution. Clin Transplant 23 (2009), 431–434.
90. Jones, R.B., Rituximab in the treatment of anti-neutrophil cytoplasm antibody-associated vasculitis. Nephron Clin Pract 128 (2014), 243–249.
91. Elsegeiny, W., Eddens, T., Chen, K., Kolls, J.K., Anti-CD20 antibody therapy and susceptibility to Pneumocystis pneumonia. Infect Immun 83 (2015), 2043–2052.
92. Kronbichler, A., Jayne, D.R., Mayer, G., Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis. Eur J Clin Invest 45 (2015), 346–368.
93. Jarrousse, B., Guillevin, L., Bindi, P., Hachulla, E., Leclerc, P., Gilson, B., et al. Increased risk of Pneumocystis carinii pneumonia in patients with Wegener's granulomatosis. Clin Exp Rheumatol 11 (1993), 615–621.
94. Palsson, R., Choi, H.K., Niles, J.L., Opportunistic infections are preceded by a rapid fall in antineutrophil cytoplasmic antibody (ANCA) titer in patients with ANCA associated vasculitis. J Rheumatol 29 (2002), 505–510.
95. McGregor, J.G., Negrete-Lopez, R., Poulton, C.J., Kidd, J.M., Katsanos, S.L., Goetz, L., et al. Adverse events and infectious burden, microbes and temporal outline from immunosuppressive therapy in antineutrophil cytoplasmic antibody-associated vasculitis with native renal function. Nephrol Dial Transplant 30:Suppl. 1 (2015), i171–i181.
96. Torres, A., Dominguez-Gil, B., Carreno, A., Hernandez, E., Morales, E., Segura, J., et al. Conservative versus immunosuppressive treatment of patients with idiopathic membranous nephropathy. Kidney Int 61 (2002), 219–227.
97. Yale, S.H., Limper, A.H., Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc 71 (1996), 5–13.
98. Cartin-Ceba, R., Golbin, J.M., Keogh, K.A., Peikert, T., Sanchez-Menendez, M., Ytterberg, S.R., et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center. Arthritis Rheum 64 (2012), 3770–3778.
99. Charles, P., Neel, A., Tieulie, N., Hot, A., Pugnet, G., Decaux, O., et al. Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients. Rheumatology 53 (2014), 532–539.
100. Hugle, B., Solomon, M., Harvey, E., James, A., Wadhwa, A., Amin, R., et al. Pneumocystis jiroveci pneumonia following rituximab treatment in Wegener's granulomatosis. Arthritis Care Res 62 (2010), 1661–1664.
101. Martin-Garrido, I., Carmona, E.M., Specks, U., Limper, A.H., Pneumocystis pneumonia in patients treated with rituximab. Chest 144 (2013), 258–265.
102. Besada, E., Nossent, J.C., Should Pneumocystis jiroveci prophylaxis be recommended with rituximab treatment in ANCA-associated vasculitis?. Clin Rheumatol 32 (2013), 1677–1681.
103. Guillevin, L., Pagnoux, C., Karras, A., Khouatra, C., Aumaitre, O., Cohen, P., et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 371 (2014), 1771–1780.
104. Weng, C.T., Liu, M.F., Weng, M.Y., Lee, N.Y., Wang, M.C., Lin, W.C., et al. Pneumocystis jirovecii pneumonia in systemic lupus erythematosus from southern Taiwan. J Clin Rheumatol 19 (2013), 252–258.
105. Sato, M., Ito, S., Ogura, M., Kamei, K., Impact of rituximab on height and weight in children with refractory steroid-dependent nephrotic syndrome. Pediatr Nephrol 29 (2014), 1373–1379.
106. Czarniak, P., Zaluska-Lesniewska, I., Zagozdzon, I., Zurowska, A., Difficulties in diagnosing severe Pneumocystis jiroveci pneumonia after rituximab therapy for steroid-dependent nephrotic syndrome. Pediatr Nephrol 28 (2013), 987–988.
107. Fritzsche, C., Riebold, D., Munk-Hartig, A., Klammt, S., Neeck, G., Reisinger, E., High prevalence of Pneumocystis jirovecii colonization among patients with autoimmune inflammatory diseases and corticosteroid therapy. Scand J Rheumatol 41 (2012), 208–213.
108. Shelton, E., Yong, M., Cohney, S., Late onset Pneumocystis pneumonia in patients receiving rituximab for humoral renal transplant rejection. Nephrol Ther 14 (2009), 696–699.
109. Green, H., Paul, M., Vidal, L., Leibovici, L., Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc 82 (2007), 1052–1059.
110. Fishman, J.A., Rubin, R.H., Infection in organ-transplant recipients. N Engl J Med 338 (1998), 1741–1751.
111. Uezono, S., Sato, Y., Hara, S., Hisanaga, S., Fukudome, K., Fujimoto, S., et al. Outcome of ANCA-associated primary renal vasculitis in Miyazaki Prefecture. Intern Med 46 (2007), 815–822.
112. Tan, C.S., Koralnik, I.J., Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 9 (2010), 425–437.
113. Carson, K.R., Evens, A.M., Richey, E.A., Habermann, T.M., Focosi, D., Seymour, J.F., et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the research on adverse drug events and reports project. Blood 113 (2009), 4834–4840.
114. Lima, M.A., Progressive multifocal leukoencephalopathy: new concepts. Arq Neuropsiquiatr 71 (2013), 699–702.
115. Molloy, E.S., Calabrese, C.M., Calabrese, L.H., The risk of progressive multifocal leukoencephalopathy in the biologic era: prevention and management. Rheum Dis Clin North 43 (2017), 95–109.
116. Molloy, E.S., Calabrese, L.H., Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk?. Autoimmun Rev 8 (2008), 144–146.
117. FDA, Information for healthcare professionals: rituximab (marketed as Rituxan). 2006.
118. Pugnet, G., Pagnoux, C., Bezanahary, K., Ly, K.H., Vidal, E., Guillevin, L., Progressive multifocal encephalopathy after cyclophosphamide in granulomatosis with polyangiitis (Wegener) patients: case report and review of literature. Clin Exp Rheumatol 31 (2013), S62–S64.
119. Wall, N., Harper, L., Complications of long-term therapy for ANCA-associated systemic vasculitis. Nat Rev Nephrol 8 (2012), 523–532.
120. Calabrese, L.H., Molloy, E.S., Huang, D., Ransohoff, R.M., Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease. Arthritis Rheum 56 (2007), 2116–2128.
121. Loyaga-Rendon, R.Y., Taylor, D.O., Koval, C.E., Progressive multifocal leukoencephalopathy in a heart transplant recipient following rituximab therapy for antibody-mediated rejection. Am J Transplant 13 (2013), 1075–1079.
122. Calabrese, L.H., Molloy, E., Berger, J., Sorting out the risks in progressive multifocal leukoencephalopathy. Nat Rev Rheumatol 11 (2015), 119–123.
123. Manrique, J., Cravedi, P., Role of monoclonal antibodies in the treatment of immune-mediated glomerular diseases. Nefrologia 34 (2014), 388–397.
124. Bang, S.Y., Lee, C.K., Kang, Y.M., Kim, H.A., Suh, C.H., Chung, W.T., et al. Multicenter retrospective analysis of the effectiveness and safety of rituximab in Korean patients with refractory systemic lupus erythematosus. Autoimmune Dis, 2012, 2012, 565039.
125. Trivin, C., Tran, A., Moulin, B., Choukroun, G., Gatault, P., Courivaud, C., et al. Infectious complications of a rituximab-based immunosuppressive regimen in patients with glomerular disease. Clin Kidney J, 2016, sfw101.
126. Kelesidis, T., Daikos, G., Boumpas, D., Tsiodras, S., Does rituximab increase the incidence of infectious complications? A narrative review. Int J Infect Dis 15 (2011), e2–16.
127. Tony, H.P., Burmester, G., Schulze-Koops, H., Grunke, M., Henes, J., Kotter, I., et al. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther, 13, 2011, R75.
128. Ninan, M.J., Liu, Y., Kuo, Y.F., Goodwin, J.S., Hospitalization for toxicity in patients treated with rituximab. Am J Clin Oncol, 18, 2014 Sep [epub ahead of print].
129. Md Yusof, M.Y., Vital, E.M., Buch, M.H., B cell therapies, approved and emerging: a review of infectious risk and prevention during use. Curr Rheumatol Rep, 17, 2015, 65.
130. van Vollenhoven, R.F., Fleischmann, R.M., Furst, D.E., Lacey, S., Lehane, P.B., Longterm safety of rituximab: final report of the rheumatoid arthritis global clinical trial program over 11 years. J Rheumatol 42 (2015), 1761–1766.
131. Hogan, J., Avasare, R., Radhakrishnan, J., Is newer safer? Adverse events associated with first-line therapies for ANCA-associated vasculitis and lupus nephritis. Clin J Am Soc Nephrol 9 (2014), 1657–1667.
132. Munyentwali, H., Bouachi, K., Audard, V., Remy, P., Lang, P., Mojaat, R., et al. Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease. Kidney Int 83 (2013), 511–516.
133. Kong, W.Y., Swaminathan, R., Irish, A., Our experience with rituximab therapy for adult-onset primary glomerulonephritis and review of literature. Int Urol Nephrol 45 (2013), 795–802.
134. Kamar, N., Milioto, O., Puissant-Lubrano, B., Esposito, L., Pierre, M.C., Mohamed, A.O., et al. Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients. Am J Transplant 10 (2010), 89–98.
135. Baek, C.H., Yang, W.S., Park, K.S., Han, D.J., Park, J.B., Park, S.K., Infectious risks and optimal strength of maintenance immunosuppressants in rituximab-treated kidney transplantation. Nephron Extra 2 (2012), 66–75.
136. Kourbeti, I.S., Ziakas, P.D., Mylonakis, E., Biologic therapies in rheumatoid arthritis and the risk of opportunistic infections: a meta-analysis. Clin Infect Dis 58 (2014), 1649–1657.
137. Chen, Y.M., Chen, H.H., Lai, K.L., Hung, W.T., Lan, J.L., Chen, D.Y., The effects of rituximab therapy on released interferon-gamma levels in the QuantiFERON assay among RA patients with different status of Mycobacterium tuberculosis infection. Rheumatology 52 (2013), 697–704.
138. Liao, T.L., Lin, C.H., Chen, Y.M., Chang, C.L., Chen, H.H., Chen, D.Y., Different risk of tuberculosis and efficacy of isoniazid prophylaxis in rheumatoid arthritis patients with biologic therapy: a nationwide retrospective cohort study in Taiwan. PLoS One, 11, 2016, e0153217.
139. Buch, M.H., Smolen, J.S., Betteridge, N., Breedveld, F.C., Burmester, G., Dorner, T., et al. Rituximab consensus expert, updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 70 (2011), 909–920.
140. Lally, L., Spiera, R., B-cell-targeted therapy in systemic vasculitis. Curr Opin Rheumatol 28 (2016), 15–20.
141. Kattah, A.G., Fervenza, F.C., Roccatello, D., Rituximab-based novel strategies for the treatment of immune-mediated glomerular diseases. Autoimmun Rev 12 (2013), 854–859.
142. Petrarca, A., Rigacci, L., Caini, P., Colagrande, S., Romagnoli, P., Vizzutti, F., et al. Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. Blood 116 (2010), 335–342.
143. Wechsler, E., Yang, T., Jordan, S.C., Vo, A., Nast, C.C., Anti-glomerular basement membrane disease in an HIV-infected patient. Nat Clin Pract Nephrol 4 (2008), 167–171.
144. CDC, General Recommendations on Immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). 2011.
145. van Assen, S., Agmon-Levin, N., Elkayam, O., Cervera, R., Doran, M.F., Dougados, M., et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 70 (2011), 414–422.
146. van Assen, S., Elkayam, O., Agmon-Levin, N., Cervera, R., Doran, M.F., Dougados, M., et al. Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: a systematic literature review for the European League against rheumatism evidence-based recommendations for vaccination in adult patients with auto-immune inflammatory rheumatic diseases. Autoimmun Rev 10 (2011), 341–352.
147. van Assen, S., Holvast, A., Benne, C.A., Posthumus, M.D., van Leeuwen, M.A., Voskuyl, A.E., et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 62 (2010), 75–81.
148. St Clair, E.W., Good and bad memories following rituximab therapy. Arthritis Rheum 62 (2010), 1–5.
149. Emery, P., Fleischmann, R., Filipowicz-Sosnowska, A., Schechtman, J., Szczepanski, L., Kavanaugh, A., et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54 (2006), 1390–1400.
150. Cambridge, G., Leandro, M.J., Teodorescu, M., Manson, J., Rahman, A., Isenberg, D.A., et al. B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum 54 (2006), 3612–3622.
151. Hua, C., Barnetche, T., Combe, B., Morel, J., Effect of methotrexate, anti-tumor necrosis factor alpha, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res 66 (2014), 1016–1026.
152. Berglund, A., Willen, L., Grodeberg, L., Skattum, L., Hagberg, H., Pauksens, K., The response to vaccination against influenza A (H1N1) 2009, seasonal influenza and Streptococcus pneumoniae in adult outpatients with ongoing treatment for cancer with and without rituximab. Acta Oncol 4:53 (2015), 1212–1220.
153. Bingham, C.O. III, Looney, R.J., Deodhar, A., Halsey, N., Greenwald, M., Codding, C., et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum 62 (2010), 64–74.
154. Yri, O.E., Torfoss, D., Hungnes, O., Tierens, A., Waalen, K., Nordoy, T., et al. Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment. Blood 118 (2011), 6769–6771.
155. Eisenberg, R.A., Jawad, A.F., Boyer, J., Maurer, K., McDonald, K., Prak, E.T., et al., Sullivan, Rituximab-treated patients have a poor response to influenza vaccination. J Clin Immunol 33 (2013), 388–396.
156. Westra, J., van Assen, S., Wilting, K.R., Land, J., Horst, G., de Haan, A., et al. Rituximab impairs immunoglobulin (Ig)M and IgG (subclass) responses after influenza vaccination in rheumatoid arthritis patients. Clin Exp Immunol 178 (2014), 40–47.
157. Moulis, G., Lapeyre-Mestre, M., Mahevas, M., Montastruc, J.L., Sailler, L., Need for an improved vaccination rate in primary immune thrombocytopenia patients exposed to rituximab or splenectomy. A nationwide population-based study in France. Am J Hematol 90 (2015), 301–305.
158. Cheng, D.R., Barton, R., Greenway, A., Crawford, N.W., Rituximab and protection from vaccine preventable diseases: applying the evidence to pediatric patients. Expert Rev Vaccines 15 (2016), 1567–1574.
159. Ostensen, M., Lockshin, M., Doria, A., Valesini, G., Meroni, P., Gordon, C., et al. Update on safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugs. Rheumatology 47:Suppl. 3 (2008), iii28–iii31.
160. Friedrichs, B., Tiemann, M., Salwender, H., Verpoort, K., Wenger, M.K., Schmitz, N., The effects of rituximab treatment during pregnancy on a neonate. Haematologica 91 (2006), 1426–1427.
161. Klink, D.T., van Elburg, R.M., Schreurs, M.W., van Well, G.T., Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development. Clin Dev Immunol, 2008, 2008, 271363.
162. Gotestam Skorpen, C., Hoeltzenbein, M., Tincani, A., Fischer-Betz, R., Elefant, E., Chambers, C., et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 75 (2016), 795–810.
163. Al-Rabadi, L., Ayalon, R., Bonegio, R.G., Ballard, J.E., Fujii, A.M., Henderson, J.M., et al. Pregnancy in a patient with primary membranous nephropathy and circulating anti-PLA2R antibodies: a case report. Am J Kidney Dis 67 (2016), 775–778.
164. Pendergraft, W.F. III, McGrath, M.M., Murphy, A.P., Murphy, P., Laliberte, K.A., Greene, M.F., et al. Fetal outcomes after rituximab exposure in women with autoimmune vasculitis. Ann Rheum Dis 72 (2013), 2051–2053.
165. Sangle, S.R., Lutalo, P.M., Davies, R.J., Khamashta, M.A., D'Cruz, D.P., B-cell depletion therapy and pregnancy outcome in severe, refractory systemic autoimmune diseases. J Autoimmun 43 (2013), 55–59.
166. Ling, J., Koren, G., Challenges in vaccinating infants born to mothers taking immunoglobulin biologicals during pregnancy. Expert Rev Vaccines 15 (2016), 239–256.
167. Weber, J.C., Kuhnert, C., Breastfeeding and drug management in connective tissue and rheumatic diseases. Rev Med Interne 29 (2008), 1017–1023.
168. Tong, A., Jesudason, S., Craig, J.G., Winkelmayer, W.C., Perspectives on pregnancy in women with chronic kidney disease: systematic review of qualitative studies. Nephrol Dial Transplant 30 (2015), 652–661.
169. Hadjinicolaou, A.V., Nisar, M.K., Parfrey, H., Chilvers, E.R., Ostor, A.J., Non-infectious pulmonary toxicity of rituximab: a systematic review. Rheumatology 51 (2012), 653–662.
170. Liote, H., Liote, F., Seroussi, B., Mayaud, C., Cadranel, J., Rituximab-induced lung disease: a systematic literature review. Eur Respir J 35 (2010), 681–687.
171. Daoussis, D., Melissaropoulos, K., Sakellaropoulos, G., Antonopoulos, I., Markatseli, T.E., Simopoulou, T., et al. A multicenter, open-label, comparative study of B-cell depletion therapy with rituximab for systemic sclerosis-associated interstitial lung disease. Semin Arthritis Rheum, 2016 Oct 13 [epub ahead of print].
172. Giuggioli, D., Lumetti, F., Colaci, M., Fallahi, P., Antonelli, A., Ferri, C., Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature. Autoimmun Rev 14 (2015), 1072–1078.
173. Ng, K.H., Dearden, C., Gruber, P., Rituximab-induced Takotsubo syndrome: more cardiotoxic than it appears?. BMJ Case Rep, 2015, 2015.
174. Kasi, P.M., Tawbi, H.A., Oddis, C.V., Kulkarni, H.S., Clinical review: serious adverse events associated with the use of rituximab - a critical care perspective. Crit Care, 16, 2012, 231.
175. Lowndes, S., Darby, A., Mead, G., Lister, A., Stevens-Johnson syndrome after treatment with rituximab. Ann Oncol 13 (2002), 1948–1950.
176. Karmacharya, P., Poudel, D.R., Pathak, R., Donato, A.A., Ghimire, S., Giri, S., et al. Rituximab-induced serum sickness: a systematic review. Semin Arthritis Rheum 45 (2015), 334–340.
177. van Daalen, E.E., Rizzo, R., Kronbichler, A., Wolterbeek, R., Bruijn, J.A., Jayne, D.R., et al. Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis. Ann Rheum Dis, 2016 [epub ahead of print].
178. Jayne, D., Role of rituximab therapy in glomerulonephritis. J Am Soc Nephrol 21 (2010), 14–17.
179. Fervenza, F.C., Canetta, P.A., Barbour, S.J., Lafayette, R.A., Rovin, B.H., Aslam, N., et al. A multicenter randomized controlled trial of rituximab versus cyclosporine in the treatment of idiopathic membranous nephropathy (MENTOR). Nephron 130 (2015), 159–168.
180. Rojas-Rivera, J., Fernandez-Juarez, G., Ortiz, A., Hofstra, J., Gesualdo, L., Tesar, V., et al. A European multicentre and open-label controlled randomized trial to evaluate the efficacy of Sequential treatment with TAcrolimus-Rituximab versus steroids plus cyclophosphamide in patients with primary MEmbranous Nephropathy: the STARMEN study. Clin Kidney J 8 (2015), 503–510.